Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Abstract Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects. Cangrelor has been tested in the large CHAMPION (Cangrelor Versus Standard Therapy to Achieve Optimal Management...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wiley
2021-07-01
|
| Sarja: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Aiheet: | |
| Linkit: | https://www.ahajournals.org/doi/10.1161/JAHA.121.022125 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|